Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05872763 | A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery | completed | — | 901 | Hoffmann-La RocheINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06228508 | Molecular Diagnosis of Lung Cancer Via Bronchoscopy: The Significance of Bronchial Liquid Biopsy (ctDNA and ctRNA)(BiliBro) | completed | — | 79 | Assistance Publique - Hôpitaux de ParisOTHER | 1 |
| Aug 13, 2026 |
| clinicaltrials |
| NCT04348149 | Lindera Obtusiloba for Non-small Cell Lung Cancer | completed | N/A | 20 | Jun-Yong ChoiOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04769388 | Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib(FLAME) | completed | Phase 2 | 80 | Beijing Cancer Prevention & Treatment SocietyOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03776253 | Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer | completed | N/A | 39 | City of Hope Medical CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03924050 | Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI | completed | Phase 3 | 440 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05785845 | Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer | completed | N/A | 17 | Washington University School of MedicineOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06249854 | Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 26 | Korea Institute of Oriental MedicineOTHER_GOV | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04640259 | Epidemiology of Young Lung Cancer - Survey(EoYLC) | completed | — | 187 | Addario Lung Cancer Medical InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06448793 | Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments | completed | — | 650 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06139419 | The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC | completed | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06532032 | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer(swalloWTail) | completed | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 31, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05258279 | Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | completed | Phase 2 | 30 | Juntendo UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03581487 | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04563871 | Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)(BLOSSOM) | completed | Phase 2 | 73 | Sehhoon ParkOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04158440 | Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC | completed | Phase 3 | 501 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04776447 | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)(APOLO) | completed | Phase 2 | 38 | Fundación GECPOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04702009 | Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 33 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04826341 | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | completed | Phase 1 / Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06477055 | The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer(RAISE) | completed | — | 43 | Hunan Province Tumor HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07192926 | Body Composition and Blood-Based Prognostic Markers in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer(SARC-CTI) | completed | — | 155 | Ankara Etlik City HospitalOTHER_GOV | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04919369 | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 | 18 | Dwight OwenOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05775289 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | completed | Phase 2 | 182 | Hoffmann-La RocheINDUSTRY | 11 | Jul 20, 2026 | clinicaltrials |
| NCT03383302 | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects(STILE) | completed | Phase 1 / Phase 2 | 36 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04592523 | A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea | completed | — | 271 | TakedaINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | completed | Phase 1 | 145 | Coherus Oncology, Inc.INDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT07068139 | AI-Based Prediction of Stage and Survival in Non-Small Cell Lung Cancer: A Retrospective Study | completed | — | 156 | Hilkat Fatih ElverdiOTHER | 0 | Jul 15, 2026 | clinicaltrials |
| NCT01964157 | An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | completed | Phase 2 | 32 | Yonsei UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03519971 | Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer | completed | Phase 3 | 328 | AstraZenecaINDUSTRY | 14 | Jul 14, 2026 | clinicaltrials |
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 | clinicaltrials |
| NCT02635009 | Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 418 | NRG OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT06678555 | A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out. | completed | — | 22 | PfizerINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04487756 | Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer(VENEZO-LUNG) | completed | Phase 1 / Phase 2 | 20 | Instituto Oncológico Dr RosellOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04905316 | A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer(CHORUS) | completed | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06049966 | Atezolizumab in Large Cell Neuroendocrine Carcinoma(LANCE) | completed | Phase 1 | 22 | Oncology Center of Biochemical Education And ResearchOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06038526 | Evaluation of Canakinumab in High-Risk Former-Smokers | completed | Phase 2 | 41 | Peter ShieldsOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT02843568 | Improving Pulmonary Function Following Radiation Therapy | completed | N/A | 122 | University of Wisconsin, MadisonOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | completed | Phase 2 | 161 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03603002 | Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer | completed | N/A | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients(RAMP204) | completed | Phase 1 / Phase 2 | 12 | Verastem, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07682012 | LungVision AI-Augmented Fluoroscopic Navigation for Intraoperative Pulmonary Nodule Localization | completed | N/A | 14 | Tri-Service General Hospital (TSGH)OTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02911259 | Suction on Post-Operative Chest Tubes(SPOCT) | completed | N/A | 230 | Rigshospitalet, DenmarkOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04116970 | Endobronchial Ultrasound-Guided Transbronchial Needle-Aspiration With Suction in Obtaining Samples From Patients With Suspected Nodal Metastatic Lung Cancer(EBUS-Suction) | completed | N/A | 50 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03801304 | Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer(VinMetAtezo) | completed | Phase 2 | 80 | University Hospital, BrestOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04248829 | Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) | completed | Phase 3 | 393 | Yuhan CorporationINDUSTRY | 13 | Jun 29, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 13, 2026source: clinicaltrials